Analysts have revised the one-year price target for Pulse Biosciences (NASDAQ: PLSE) to $51.82 per share, a 12.27% increase from the previous estimate of $46.16 dated August 25, 2026. This target, however, represents a decrease of 6.11% from the latest closing price of $55.19 on September 15, 2026. The target range has widened significantly, now spanning from a low of $35.35 to a high of $76.65, reflecting a change of +61.64%.
Pulse Biosciences has seen three consecutive upward revisions in its consensus target since June 2026, when the mean target was $31.28. It rose to $32.98 on August 4, 2026, and to $46.16 by August 28, 2026, marking a total increase of 65.65% since June 8, 2026. Analyst sentiment is largely positive, with 90% of recommendations as of September 1, 2026, classified as strong buy or buy.
The company operates in the biomedical sector, focusing on therapeutic technologies through its Nano-Pulse Stimulation (NPS) platform. Recent analyst actions include new coverage initiated by Freedom Capital Markets and Needham, both assigning a Buy grade in September and August 2026, respectively.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
